

# DAY 1 – April 29, 2021

## Opioid Agonist Therapy 101: An Introduction to Clinical Practice Program Schedule

- 0800 – 0820 Check In - go to [www.slido.com](http://www.slido.com) (event code) #OATEVAL1
- 0820 – 0840 Orientation to the Workshop (Includes pre-test – [link to test sent via email](#))
- 0840 – 0900 Round Table Introductions**
- 0900 – 0920 A review of Opioid Use Disorder and emerging inpatient and community disease patterns**  
*Marina Reinecke*
- 0920 – 1020 Treatment approaches: The evidence and how it informs local practice (includes discussion on abstinence vs. harm reduction, naloxone, and psychosocial support groups)**  
*Erin Knight*
- 1020 – 1035 Break
- 1035 – 1105 Now what? Includes things to consider starting out in OAT practice, who's doing what out there and the prescribing approval process**  
*Marina Reinecke*
- 1105 – 1150 Pharmacology of methadone and buprenorphine/naloxone and prescriber-pharmacist collaborative care**  
*Mike Sloan*
- 1150 – 1220 Lunch break
- 1220 – 1305 The Comprehensive Patient Assessment**  
*Talia Carter*
- 1305 – 1415 From Initiation to the Maintenance phase: Dose adjustments, Urine toxicology, Carries, Split dosing, Management of Concurrent alcohol abuse, and Insomnia**  
*Erin Knight*
- 1415 – 1445 Benzodiazepines and opioid agonist treatment: A practical approach to care**  
*Marina Reinecke*
- 1445 – 1500 Break
- 1500 – 1550 Break-out session # 1 (Pharmacists) Integrating Opioid Agonist Therapy into Pharmacy Practice - Part 1: Examining the Current Guidelines**  
*Ashley Ewasiuk*
- 1500 – 1550 Break-out session # 1 (Prescribers) Standardized patient (Talia & Mike) interviews - 2 groups**  
*(Marina & Erin facilitate)*
- 1550 – 1630 Break-out session # 2 (Prescribers & Pharmacists) Case discussion and role play**  
*(Marina & Ashley facilitate)*

\*\*Day 1 Evaluation forms; go to [www.slido.com](http://www.slido.com) #OATEVAL1